enzastaurin has been researched along with Angiogenesis, Pathologic in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (58.33) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Butowski, N; Cha, S; Chang, SM; Essock-Burns, E; Lupo, JM; Molinaro, AM; Nelson, SJ | 1 |
| Calcagno, SR; Fields, AP; Krishna, M; Leitges, M; Murray, NR; Rak, S | 1 |
| Gonelli, A; Guerrini, R; Mischiati, C; Salvadori, S; Voltan, R; Zauli, G | 1 |
| Kim, KW; Lu, B; Moretti, L; Niermann, KJ; Quarles, CC; Tawtawy, MN; Tu, T; Willey, CD; Xiao, D | 1 |
| Hayes, DN; Shores, CG; Yin, X | 1 |
| Ciaccio, MF; Cohen, EE; Jones, RB; Kuo, WL; Lingen, M; Liu, J; Rosner, MR; Seiwert, TY | 1 |
| Anderson, KC; Podar, K | 1 |
| Teicher, BA | 1 |
| Gökmen-Polar, Y; Sledge, GW | 1 |
| Anderson, KC; Breitkreutz, I; Chauhan, D; Hideshima, T; Lin, BK; McMillin, D; Munshi, N; Podar, K; Raab, MS; Tai, YT; Zhang, J | 1 |
| Dudek, AZ; Ericson, ME; Farassati, F; Gallus, NJ; Jasinski, P; Terai, K; Zwolak, P | 1 |
| Chen, YB; LaCasce, AS | 1 |
4 review(s) available for enzastaurin and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Perspectives of protein kinase C (PKC) inhibitors as anti-cancer agents.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bryostatins; Cell Cycle; Cell Transformation, Neoplastic; Clinical Trials as Topic; Humans; Indoles; Neoplasm Metastasis; Neovascularization, Pathologic; Plant Extracts; Protein Kinase C-delta; Protein Kinase C-epsilon; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-mdm2; Tumor Suppressor Protein p53 | 2009 |
Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Benzenesulfonates; Hematologic Neoplasms; Humans; Indoles; Multiple Myeloma; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A; Wnt Signaling Pathway | 2011 |
Protein kinase C-beta as a therapeutic target in breast cancer.
Topics: Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Indoles; Neovascularization, Pathologic; Protein Kinase C; Protein Kinase C beta; Vascular Endothelial Growth Factor A | 2006 |
Enzastaurin.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Clinical Trials as Topic; Enzyme Activation; Humans; Indoles; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase C; Protein Kinase C beta; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Salvage Therapy; Signal Transduction; Vascular Endothelial Growth Factor A | 2008 |
8 other study(ies) available for enzastaurin and Angiogenesis, Pathologic
| Article | Year |
|---|---|
The effects of anti-angiogenic therapy on the formation of radiation-induced microbleeds in normal brain tissue of patients with glioma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Brain Neoplasms; Cerebral Hemorrhage; Female; Glioma; Humans; Indoles; Magnetic Resonance Imaging; Male; Middle Aged; Neovascularization, Pathologic; Radiotherapy; Treatment Outcome | 2016 |
Protein kinase Cbeta is an effective target for chemoprevention of colon cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; beta Catenin; Cell Differentiation; Cell Division; Colonic Neoplasms; Enzyme Inhibitors; Epithelial Cells; Female; Humans; Indoles; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Protein Kinase C; Protein Kinase C beta | 2009 |
Enzastaurin (LY317615), a protein kinase C beta selective inhibitor, enhances antiangiogenic effect of radiation.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Combined Modality Therapy; Endothelium, Vascular; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Mice; Neovascularization, Pathologic; Protein Kinase C; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Radiation Tolerance; Radiation-Sensitizing Agents; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2010 |
Antitumor activity of enzastaurin as radiation sensitizer in head and neck squamous cell carcinoma.
Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Death; Cell Line, Tumor; Disease Models, Animal; Female; Flow Cytometry; Head and Neck Neoplasms; Humans; Immunohistochemistry; Indoles; Mice; Mice, Nude; Neovascularization, Pathologic; Protein Kinase C; Protein Kinase C beta; Radiation-Sensitizing Agents; Random Allocation; Sensitivity and Specificity; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays | 2011 |
Effect of complementary pathway blockade on efficacy of combination enzastaurin and rapamycin.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Female; Head and Neck Neoplasms; In Situ Nick-End Labeling; Indoles; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Protein Kinase Inhibitors; Sirolimus; Squamous Cell Carcinoma of Head and Neck; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2011 |
Hypoxia, tumor endothelium, and targets for therapy.
Topics: Animals; Cell Line, Tumor; Endothelium, Vascular; Gene Expression; Humans; Hypoxia; Indoles; Mice; Models, Biological; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2005 |
Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl).
Topics: Administration, Oral; Animals; Cell Communication; Coculture Techniques; Cytokines; Drug Delivery Systems; Enzyme Activation; Humans; Indoles; Mice; Multiple Myeloma; Neovascularization, Pathologic; Phorbol Esters; Phosphorylation; Protein Isoforms; Protein Kinase C; Stromal Cells; Transplantation, Heterologous; Tumor Burden; Tumor Cells, Cultured | 2007 |
Protein kinase C-beta inhibitor enzastaurin (LY317615.HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis.
Topics: Animals; Apoptosis; Bone Neoplasms; Caspases; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelial Cells; Female; Indoles; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Mice, SCID; Neovascularization, Pathologic; Osteoclasts; Pain; Protein Kinase C; Protein Kinase C beta; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; ras Proteins; Signal Transduction; Tumor Burden | 2008 |